About BerGenBio
OSE: BGBIO
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
AXL: a promising target to treat life-threatening diseases
Key Roles of AXL in Severe Respiratory Infections
- Dampens innate immune response
- Prevents lung tissue repair
- Reduces viral entry into cell
SRI
Key Roles of the AXL in Cancer
- Invasion/Migration
- Drug resistance
- Proliferation
- Survival
- Immune suppression
Cancer
Properties of Bemcentinib
- Orally bioavailable small molecule TKI
- Potent, selective AXL inhibition
- Once-a-day administration
- Favorable safety profile
- Single agent and combination activity
Bemcentinib (bgb324)
Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL to develop a new therapeutic approach for lung cancer patients.
Partnerships based on BerGenBio’s pioneering R&D are being employed strategically with an extensive network of leading clinical sites and key opinion leaders. These collaborations are designed to optimally position the company's investigational product candidate.